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Translational control depends on phosphorylation of
eIF2a by PKR-like ER kinase (PERK). To examine the
role of PERK in cognitive function, we selectively
disrupted PERK expression in the adult mouse fore-
brain. In the prefrontal cortex (PFC) of PERK-
deficient mice, eIF2a phosphorylation and ATF4
expression were diminished and were associated
with enhanced behavioral perseveration, decreased
prepulse inhibition, reduced fear extinction, and
impaired behavioral flexibility. Treatment with the
glycine transporter inhibitor SSR504734 normalized
eIF2aphosphorylation, ATF4 expression, and behav-
ioral flexibility in PERK-deficient mice. Moreover, the
expression levels of PERK and ATF4 were reduced in
the frontal cortex of human patients with schizo-
phrenia. Together, our findings reveal that PERK
plays a critical role in information processing and
cognitive function and that modulation of eIF2a
phosphorylation andATF4 expressionmay represent
an effective strategy for treating behavioral inflexi-
bility associated with several neurological disorders
such as schizophrenia.
INTRODUCTION
Inmammals, long-lastingmemory formation requires newmRNA
and protein synthesis (Costa-Mattioli et al., 2009; Kandel, 2001;
Kelleher et al., 2004; Richter and Klann, 2009). The translation of
mRNAs is highly regulated at the level of initiation by numerous
translational controlmolecules, including the translation initiation
factor eIF2 (Sonenberg and Dever, 2003). During this rate-
limiting step, eIF2 interacts with initiator tRNA and GTP to facil-
itate loading of the ternary complex onto the 40S ribosomal
subunit, which is essential for new rounds of protein synthesis
(Harding et al., 1999). Although phosphorylation of the a subunit
of eIF2 results in general inhibition of translation, it paradoxically
stimulates the translation of several upstream open reading676 Cell Reports 1, 676–688, June 28, 2012 ª2012 The Authorsframe (uORF)-containing mRNAs, including the transcriptional
modulator activating transcription factor 4 (ATF4) (Vattem and
Wek, 2004). Notably, ATF4 and its homologs play critical roles
as repressors of cAMP response element-binding protein
(CREB)-mediated synaptic plasticity and memory in diverse
phyla (Abel et al., 1998; Bartsch et al., 1995; Chen et al., 2003).
Thus, eIF2a phosphorylation controls two distinct processes
that are essential for the consolidation of new memories: de
novo general protein synthesis, and gene-specific translation
of ATF4mRNA. Furthermore, reduction of eIF2a phosphorylation
in mice lacking the eIF2a kinase GCN2 and in heterozygous
knockin mice with a mutation on serine 51 of eIF2a results
in a lowered threshold for inducing long-lasting late-phase
long-term potentiation (L-LTP) and consolidation of long-term
memory (Costa-Mattioli et al., 2005, 2007). Moreover, mice
harboring a deletion of the double-stranded (ds) RNA-activated
protein kinase (PKR) show a similar decrease in threshold for
inducing L-LTP and consolidation of long-term memory (Zhu
et al., 2011). Conversely, increased eIF2a phosphorylation in
transgenic mice overexpressing PKR causes increased expres-
sion of ATF4, impaired L-LTP, and memory deficits (Jiang et al.,
2010). Collectively, these findings suggest that the proper regu-
lation of eIF2a phosphorylation is required for normal synaptic
plasticity and memory.
The PKR-like ER kinase (PERK) was initially characterized
as a ubiquitously expressed ER-localized protein kinase that
phosphorylates eIF2a to rapidly reduce protein synthesis during
ER stress (Harding et al., 2000). Global inactivation of PERK in
mice results in multiple developmental defects, including early-
onset diabetes, growth retardation, skeletal abnormalities, and
pancreatic atrophy (Harding et al., 2001; Zhang et al., 2002).
Consistent with this, mutations in the human PERK gene
(EIF2AK3) causesWolcott-Rallison syndrome (WRS), a rare auto-
somal recessive disorder characterized by permanent neonatal
diabetes, multiple epiphyseal dysplasia, liver dysfunction, and
pancreas insufficiency (Dele´pine et al., 2000; Julier and Nicolino,
2010; Rubio-Cabezas et al., 2009). In some cases of WRS,
clinical features associated with mental retardation develop in
patients (Dele´pine et al., 2000; Reis et al., 2011; Sene´e et al.,
2004; Thornton et al., 1997). Moreover, cell lines lacking either
tuberous sclerosis complex (TSC) 1 or TSC2, the TSC proteins,
Figure 1. Forebrain-Specific Deletion of
Perk Suppresses eIF2a Phosphorylation
and ATF4 Expression in the PFC
(A) Schematic for the conditional allele for Perk.
In the top view black triangles represent two
loxP sites flanking exons 7–9 (E7–E9) of the Perk
gene, and gray boxes represent primers (568F
and 568R1) designed to detect recombination.
Middle view shows that upon recombination with
CaMKIIa-Cre, Perk is deleted in a forebrain-
specificmanner. Bottom view is PCR identification
of alleles of PerkloxP and CaMKIIa-driven Cre.
(B) Representative western blot analysis confirm-
ing disruption of PERK in hippocampal area CA1.
(C) Top view illustrates Nissl-stained coronal
sections of PFC. Bottom view shows whole brain
from WT and PERK cKO mice.
(D) Representative western blot showing
CaMKIIa-driven Cre disruption of PERK in other
regions of the brain fromWT and PERK cKOmice.
(E) Representative western blot showing that
PERK levels in cKO mice are expressed at similar
levels to those in WT mice in tissues outside the
central nervous system.
(F) Immunohistochemical detection of phosphor-
ylated eIF2a in layer II/III of the mPFC showing
decreased expression in PERK cKO (right panel)
compared to WT (left panel). Scale bar, 200 mm.
(G) Representative western blot showing
decreased ATF4 expression in the PFC of PERK
cKO mice compared to their WT littermates.
Quantification of PERK, eIF2a phosphorylation,
and ATF4 expression from the western blot
analyses is shown in Figure S1.and both mouse and human tumors from TSC model mice and
patients with TSC, respectively, exhibit activation of the PERK-
eIF2a axis (Ozcan et al., 2008). Together, these analyses suggest
a crucial role for PERK in normal cellular homeostasis, growth,
viability, and development. However, the precise role of PERK
in memory formation and cognition has not been explored.
Given that PERK functions as a critical modulator of a number
of cellular processes requiring precise translational control, we
explored the role of PERK in regulating protein synthesis-depen-
dent cognitive function in the mammalian brain. Here, we show
that a targeted disruption of PERK in the mouse forebrain results
in significant reduction of phosphorylated eIF2a and ATF4
expression in the prefrontal cortex (PFC). Behavioral studies
with PERK-deficient mice revealed multiple phenotypes con-
sistent with impaired cognition and information processing.
Moreover, treatment with the glycine transporter inhibitor
SSR504734 normalized eIF2a phosphorylation and ATF4
expression, and restored behavioral flexibility in the PERK
mutant mice. Furthermore, the molecular deficits observed in
the mutant mice were recapitulated in the frontal cortex of
patients with schizophrenia, but not in patients with bipolar
disorder. These findings expand the repertoire of PERK as
a regulator of translational control to include cognitive processes
in the adult brain and highlight the modulation of eIF2a phos-
phorylation as a key site for influencing translational control
underlying the pathophysiology of cognitive deficits commonly
associated with neurological disorders.RESULTS
PERK Regulates eIF2a Phosphorylation and ATF4
Expression in the Brain
To evaluate the precise role of PERK in translation-dependent
forms of memory in the mammalian brain, we generated mice
containing a forebrain-specific CamkIIa-Cre transgene (Tsien
et al., 1996) and conditional alleles of Perk (Zhang et al., 2002)
(PerkloxP; Figure 1A). The onset of Cre activity occurs at
approximately 2–3 weeks after birth (Tsien et al., 1996), permitt-
ing normal brain development in the presence of Perk. The
CamkIIa-Cre; PerkloxP/loxP conditional knockout mice (PERK
cKO hereafter) contain an ablation of PERK that is predominantly
limited to the forebrain. The presence of the conditional PerkloxP
allele and Cre transgene was determined using PCR-specific
primers (Figure 1A). Western blot assays confirmed efficient
Cre-mediated deletion of PerkloxP in several areas of the fore-
brain isolated from PERK cKO mice, including the hippocampus
and the PFC (Figures 1B and 1D; Figure S1A). Despite the reduc-
tion of PERK in these regions, Nissl-stained sections indicated
that mutant mice did not show gross alterations in brain
morphology compared to their wild-type (WT) littermates (Fig-
ure 1C). Notably, the PFC region harbored the greatest ablation
of PERK, which was correlated with a significant reduction of
phosphorylated eIF2a (Figures 1D and S1B). To confirm that
the genetic disruption was specifically restricted to the forebrain,
we examined PERK levels in the cerebellum, muscle, andCell Reports 1, 676–688, June 28, 2012 ª2012 The Authors 677
Figure 2. Disruption of PERK-Regulated Translation in the PFCDoes
Not Alter Protein Synthesis
(A) Left view is a western blot image showing newly synthesized proteins
labeled with puromycin using the SUnSET technique (see Experimental
Procedures). Coronal prefrontal slices from WT and PERK cKO mice were
treated with puromycin (5 mg/ml) for 45 min. Right view shows that protein
synthesis levels remain unaltered between both genotypes. (cntl, no puro-
mycin control, n = 4; WT, n = 4; cKO, n = 4).
(B) Absorbance profile (254 nm) of WT (black trace) and PERK cKO (red trace)
prefrontal cortical fractions sedimented through a 20%–50% linear sucrose
gradient in the presence of cycloheximide.peripheral organs and observed that PERK expression was
indistinguishable between mutant and WT mice (Figures 1D,
1E, and S1A). Moreover, examination of layer II/III of the medial
PFC (mPFC) by immunohistochemistry (IHC) showed nearly
a complete absence of phosphorylated eIF2a staining in PERK
cKO mice (Figure 1F). Although robust phosphorylation of
eIF2a can inhibit global protein synthesis, gene-specific transla-
tion of ATF4 is most sensitive to eIF2a phosphorylation (Vattem
and Wek, 2004). We observed that a decrease in eIF2a phos-
phorylation was associated with reduced ATF4 expression
(Figures 1G and S1C) in the PFC of PERK cKO mice. However,
we found that the decrease in eIF2a phosphorylation had
a minimal effect on global translation using a puromycin-based
assay adapted from the SUnSET technique that labels newly
synthesized proteins (Schmidt et al., 2009) (Figure 2A) and poly-
some-profiling analysis from sucrose gradients (Figure 2B).
Thus, these findings indicate that a forebrain-specific disruption
of PERK results in reduced eIF2a phosphorylation and ATF4
expression in the PFC.
PERK cKO Mice Show Impaired Information Processing
and Behavioral Flexibility
To examine whether the disruption of PERK resulted in altered
cognitive function, we tested male PERK cKO mice in a series
of behavioral paradigms. We examined the PERK cKO mice for678 Cell Reports 1, 676–688, June 28, 2012 ª2012 The Authorsprepulse inhibition (PPI) of the startle response, a reliable and
robust measure of sensorimotor gating and information-
processing abilities (Swerdlow et al., 2008). PPI involves a short,
low-intensity acoustic stimulus (prepulse) that inhibits the
reaction of an organism to a startling stimulus (Swerdlow et al.,
2008). The PERK cKO mice showed a deficit in PPI of the
auditory startle response compared to their WT littermates (Fig-
ure 3A). No difference between genotypes was observed with
the presentation of the startling stimulus alone, suggesting
a normal baseline startle response in PERK cKO mice (data not
shown). PERK cKO mice display significantly enhanced vertical
locomotor activity in the open field arena (Figure S2A). However,
we observed no difference between genotypes for the distance
traveled, time spent in the center zone of the open field, and in
the closed arms versus the aversive open arms of the elevated
plus maze (Figures S2B–S2D), suggesting normal anxiety levels
in PERK cKO mice. These findings indicate that disruption of
PERK-directed translational control results in deficits in informa-
tion processing and enhanced vertical activity.
To further examine the role of PERK in memory and cognitive
function, we subjected adult PERK cKOmice to behavioral tasks
that require precise cognitive control. First, we found that PERK
cKO mice exhibit enhanced preference for the familiar object in
the novel object recognition task (Figure 3B). Next, we deter-
mined that PERK cKO mice and their WT counterparts were
able to use spatial cues to learn the position of a hidden platform
(Figure 3C) in the Morris water maze (MWM), a hippocampus-
dependent water escape task (Morris, 1984). During probe trials
both genotypes showed similar preferences for the target quad-
rant of the pool that previously contained the platform (Fig-
ure S3A), suggesting that PERK cKO mice have normal spatial
reference memory. To specifically examine whether PERK is
involved in spatial reversal learning in the MWM, we switched
the location of the hidden platform to the opposite quadrant
and challenged the ability of the mice to learn the new platform
position. Notably, on the second day of reversal training, the
WT mice exhibited normal spatial reversal learning (Figure 3C;
Movie S1), but the PERK cKO mice displayed perseveration for
the originally learned platform position (Figure 3C; Movie S2).
However, these perseverative behaviors were not associated
with repetitive or obsessive-compulsive-like behavior because
the PERK cKO mice displayed normal marble burying and
grooming behavior (Figures S2E and S2F). PERK cKO mice
also spent more time in the previous training quadrant but ex-
hibited normal escape latency during the visible platform task
(Figures S3B and S3C). Taken together, these results indicate
that a forebrain-specific disruption of PERK causes enhanced
perseverative behaviors and impaired spatial reversal learning.
As a further test of our hypothesis that PERK regulates
memory and cognitive flexibility, PERK cKO mice were trained
in a Y-water maze reversal task. Briefly, mice were trained
to locate an escape platform in one arm of a water-based
Y maze. After 24 hr, the escape platform was switched to the
opposing arm, and the behavioral flexibility of the mice to learn
the new escape location was measured. The number of trials
to criterion (nine out of ten correct) was achieved at trial 30 by
all WT mice (Figure 4A; Movie S3). In contrast, 12 out of 13
mutant mice persistently swam toward the previously trained
Figure 3. PERK cKO Mice Display Reduced PPI and Enhanced Behavioral Perseveration in Novel Object Recognition and MWM Tasks
(A) PERK cKO mice exhibit impaired PPI of the acoustic startle reflex across varying prepulse intensities: 74, 78, 82, 86, and 90 dB. WT, n = 11; cKO, n = 9
(*p < 0.05, two-way repeated-measure ANOVA followed by Tukey’s post hoc test).
(B) PERK cKO mice display enhanced perseveration for the familiar object in the novel object recognition task. WT, n = 8; cKO, n = 14 (***p < 0.001, two-way
repeated-measures ANOVA).
(C) Left view illustrates escape latency across 5 days of MWM reference platform task and shows that PERK cKOmice acquired the spatial hidden platform task
similarly to WT controls. Right view shows that PERK cKO mice exhibit higher number of previous-day platform position crossing during day 2 reversal phase of
task compared to controls. WT, n = 12; cKO, n = 9 (*p < 0.05, two-way repeated-measures ANOVA, followed by Tukey’s post hoc test).
See also Figure S3 and Movies S1 and S2.arm choice, exhibiting severe behavioral inflexibility (Figure 4A).
A retraining paradigm was employed to allow these mice to
make three consecutive correct choices (Figure 4A). During
retraining a physical wall was used to block the incorrect arm;
however, PERK cKO mice continued to swim toward the
incorrect path and into the wall (Movie S4). The PERK cKO
mice required an additional 28 trials to meet this criterion (Fig-
ure S3D). Upon retraining, PERK cKO mice showed comparable
rates of reversal learning as their WT counterparts (Figure 4A).
Interestingly, PERK cKO mice exhibited normal behavioral flexi-
bility if the escape platform was switched to the adjacent arm
immediately after training on the first day (Figure 4B). This finding
suggests that the behavioral inflexibility exhibited by PERK
cKO mice requires memory consolidation, a protein synthesis-
dependent process (McGaugh, 2000). PERK cKOmice exhibited
normal motor ability on the rotarod task, suggesting that the
disruption of PERK does not affect cerebellar-dependent motor
functions (Figure S4). Together, these findings reveal that a post-
developmental disturbance of PERK is sufficient to trigger
impaired behavioral flexibility.
The behavioral results described above suggest that eIF2a
phosphorylation is normally altered during reversal learning. To
test this hypothesis and to determine whether the removal of
PERK has any effect on learning-dependent changes in eIF2aphosphorylation, PERK cKO mice and their WT littermates
were subjected to the Y-water maze reversal task, and frontal
cortices from both genotypes were harvested and assayed for
phosphorylated eIF2a 30 min following training for reversal
learning. We found that WT mice exhibited decreased eIF2a
phosphorylation after reversal learning (Figure 4C). In contrast,
although basal phosphorylation of eIF2a was reduced, there
was no further reduction in eIF2a phosphorylation in the PERK
cKO mice (Figure 4C). Furthermore, we found that mice lacking
the eIF2a kinase GCN2 exhibited normal reversal learning
(Figure S5), suggesting that behavioral flexibility is regulated
specifically by a pool of eIF2a that is normally phosphorylated
by PERK. Taken together, these findings suggest that reversal
learning normally decreases eIF2a phosphorylation and that
PERK phosphorylates a specific pool of eIF2a to regulate behav-
ioral flexibility.
Flexible behavior also is afforded by proper extinction, an
active, protein synthesis-dependent learning process driven by
the mPFC (Santini et al., 2004), which triggers the formation
of a newly updated memory that inhibits the initial memory
(Sotres-Bayon et al., 2004). In light of our findings suggesting
that PERK regulates behavioral flexibility, we next determined
whether fear extinction was compromised by the absence
of PERK. Interestingly, we found that PERK cKO mice haveCell Reports 1, 676–688, June 28, 2012 ª2012 The Authors 679
Figure 4. PERK cKO Mice Exhibit Cognitive Control Deficits and Behavioral Inflexibility
(A) Percent correct arm choice per trial block number (five trials per trial block) during training, test, reversal, and retraining phases of Y maze reversal task. (//)
denotes when 12 out of 13 PERK cKO mice had to be retrained because they continued to swim to the originally trained arm choice. WT, n = 10; cKO, n = 13
(***p < 0.001, two-way ANOVA). See also Figure S3 and Movies S3 and S4.
(B) PERK cKO mice no longer perseverate to originally trained arm choice following same-day immediate reversal training. WT, n = 8; cKO, n = 9.
(C) Western blot analysis of eIF2a phosphorylation in PFC of WT and PERK cKO mice 30 min following training and reversal learning. WT, n = 6; cKO, n = 6.
(*p < 0.05, one-way ANOVA; n.s., not significant).
(D) Left and middle views show percentage of time spent freezing across 2 days of fear extinction training protocol (15 CS presentations/day) and indicate that
PERK cKO mice exhibit impaired fear extinction learning compared to controls (*p < 0.05, two-way ANOVA). Right view illustrates percent freezing time during
long-term memory extinction test on day 3. WT, n = 8; cKO, n = 10 (*p < 0.05, Student’s t test).
All data represent mean ± SEM.impaired fear extinction memory compared to their WT litter-
mates (Figure 4D). Collectively, these findings suggest that
PERK-directed translation regulates extinction learning. More-680 Cell Reports 1, 676–688, June 28, 2012 ª2012 The Authorsover, disruption of PERK leads to profound behavioral symp-
toms associated with deficits in information processing and
cognitive function.
Figure 5. NMDARHypofunction Alters eIF2aPhos-
phorylation in the PFC
(A) Sample traces of EPSCs recorded from PFC slices of
WT (black) and PERK cKO (red) mice.
(B) Average NMDA/AMPA EPSC ratios from pyramidal
cells in layer II of the mPFC show no significant difference
between either genotype. WT, n = 16; cKO, n = 17.
(C) eIF2a phosphorylation is increased in the frontal cortex
of WT mice upon single-dose (acute) treatment with
MK-801 (0.2 mg/kg, i.p.) compared to saline. saline, n = 3;
MK-801, n = 3 (*p < 0.05, Student’s t test).
(D) Western blot analysis showing a decrease of eIF2a
phosphorylation following 15 days (chronic) MK-801
(0.1 mg/kg, i.p.) treatment. saline, n = 4; MK-801, n = 5
(*p < 0.05, Student’s t test).
All data represent mean ± SEM.NMDAR HypofunctionModulates eIF2a Phosphorylation
in the PFC
Compelling evidence suggesting a role for N-methyl-D-
aspartate receptor (NMDAR) hypofunction underlying the patho-
physiology of cognitive impairments stems from findings that
NMDAR blockers such as PCP, ketamine, and MK-801 induce
impaired working memory, behavioral flexibility, reversal learn-
ing, and extinction in mice and humans (Abdul-Monim et al.,
2006; Dix et al., 2010; Javitt and Zukin, 1991; Krystal et al.,
1994). Because the PERK-deficient mice display multiple cogni-
tive impairments associated with NMDAR hypofunction, we pro-
ceeded to record NMDAR-mediated excitatory currents in
layer II of the mPFC of PERK cKO mice and their WT littermates.
However, we found that the NMDA-to-AMPA ratio was indistin-
guishable between PERK cKO mice and their WT littermates
(Figures 5A and 5B), suggesting that NMDAR function is normal
in the PERK cKO mice. We then proceeded to determine
whether NMDAR hypofunction could cause abnormal PERK-
directed translation by determining whether administration of
MK-801 inWTmice could mimic the decreased eIF2a phosphor-
ylation observed in the PERK cKO mice. WT mice received a
single dose (acute) or 15 daily injections (chronic) of either saline
or MK-801 (0.2 mg/kg for acute; 0.1 mg/kg for chronic) via
intraperitoneal (i.p.) injections. Frontal cortices from saline- and
MK-801-treatedWTmice were harvested and assayed for phos-
phorylated eIF2a. We found that acute MK-801 treatment
enhanced eIF2a phosphorylation (Figure 5C), whereas chronic
MK-801 treatment decreased eIF2a phosphorylation (Figure 5D),
suggesting that the time course of NMDAR hypofunction bidirec-
tionally regulates eIF2a phosphorylation. Consistent with this
idea, longer-term increases in eIF2a phosphorylation elicit pro-
tein phosphatase 1/GADD34-directed feedback dephosphory-
lation of this translation factor (Marciniak et al., 2004). TheseCell Reports 1,data suggest that NMDAR hypofunction alters
eIF2a phosphorylation in the PFC.
SSR504734 Restores Cognitive Function
and PERK-Regulated Translation
One therapeutic strategy for the treatment
of impaired behavioral flexibility involves the
enhancement of NMDAR function by increasingsynaptic glycine, an NMDAR coactivator, by blocking glycine
reuptake via inhibition of glycine transporter-1 (GlyT1) (Javitt,
2008). Several previous studies have shown that the GlyT1 inhib-
itor SSR504734 (Depoorte`re et al., 2005) improves behavioral
flexibility, reversal learning, and overall cognitive function (Black
et al., 2009; Singer et al., 2009). To evaluate whether SSR504734
could rescue the cognitive impairments exhibited by the PERK
cKO mice, the Y-water maze reversal task was revisited to
test WT and PERK cKO mice following chronic administration
of SSR504734 (20 mg/kg; 21 days) by i.p. injection. Remarkably,
following chronic treatment with SSR504734, the PERK cKO
mice displayed normal reversal learning when compared to
their WT littermates (Figures 6A and 6B; Movies S5 and S6).
However, we found that chronic treatment with SSR504734 did
not reverse either the enhanced vertical activity (Figure S6A) or
the sensorimotor-gating impairment (Figure S6B) displayed by
the PERK cKO mice. These data demonstrate that chronic
SSR504734 administration can uniquely enhance cognitive
ability and restore behavioral flexibility in the PERK cKO mice.
To determine whether chronic SSR504734 treatment also
could rescue aberrant PERK-directed translation, frontal cor-
tices from SSR504734-treated WT and PERK mutant mice
were analyzed for total PERK, phosphorylated eIF2a, and ATF4
expression levels by western blotting. We found that PERK
cKO mice treated with SSR504734 had significantly enhanced
levels of phosphorylated eIF2a and increased ATF4 expression
compared to untreated PERK mutants (Figures 6D and 6E).
There was no significant difference in total PERK levels between
the treated and untreated PERK cKO mice (Figure 6C). Collec-
tively, these results indicate that chronic treatment with the
GlyT1 inhibitor SSR504734 can rescue disrupted PERK-
regulated translation in the PFC, presumably by either activating
another eIF2a kinase such as GCN2 and/or PKR or by inhibiting676–688, June 28, 2012 ª2012 The Authors 681
Figure 6. Treatment with the GlyT1 Inhibitor SSR504734 Rescues PFC-Dependent Molecular and Cognitive Deficits in PERK cKO Mice
(A) Y maze reversal task performance following 21 days of treatment with either saline (Veh) or glycine transporter-1 inhibitor (GlyT1 inh) SSR504734
(20 mg/kg, i.p.).
(B) Upon chronic GlyT1 inhibitor treatment, PERK cKOmice behave likeWT controls and require similar number of trials to meet criterion during reversal phase of
the Y maze task. See also Movies S5 and S6.
(C) Western blot analysis of basal PERK expression in PFC of WT and cKO (untreated) compared to chronic treatment with GlyT1 inhibitor.
(D) eIF2a phosphorylation is normalized in PFC of PERK cKO mice following GlyT1 inhibitor treatment.
(E) ATF4 protein expression is enhanced in PFC of PERK cKO mice following GlyT1 inhibitor treatment compared to untreated controls.
*p < 0.05, ***p < 0.001, two-way ANOVA. All data represent mean ± SEM.the protein phosphatase 1/GADD34 complex that dephosphory-
lates eIF2a (Ma and Hendershot, 2003).
Aberrant PERK-Regulated Translation in Frontal Cortex
of Patients with Schizophrenia
Upon discovering that mice with a targeted disruption of PERK
exhibit multiple behavioral features consistent with cognitive
impairments associated with several mental illnesses including
schizophrenia, we hypothesized that aberrant PERK-directed
translation might be involved in the pathophysiology of human
schizophrenia. To test this idea, we obtained postmortem human
schizophrenic frontal cortex samples and employed western
blot analysis to examine the expression of PERK, phosphoryla-
tion of eIF2a, and expression of ATF4. All samples from the
Stanley Medical Research Institute (SMRI) Array Collection
were matched for age, sex, and race. A summary of the relevant
patient demographic information is provided in Table S1.
Spearman correlation analysis showed no significant effect of
age, brain pH, postmortem interval (PMI), or lifetime anti-
psychotic usage on the levels of PERK or ATF4 expression682 Cell Reports 1, 676–688, June 28, 2012 ª2012 The Authors(Table S2). Brain pH and PMI were negatively correlated with
eIF2a phosphorylation and total eIF2a levels. ANCOVA with pH
andPMI as covariates failed to confirm thediagnostic differences
initially observedwithANOVA for the eIF2aphosphorylation anal-
ysis (data not shown). Thus, we were unable to assess the regu-
lation of eIF2a phosphorylation in postmortem schizophrenic
samples. Frontal cortex samples from normal control patients
displayed a considerable level of PERK, which was significantly
reduced in the schizophrenia samples (Figure 7A). Moreover,
ATF4 expression was markedly reduced in the schizophrenia
brains compared to controls (Figure 7B). To investigate how
broadly PERK-directed translation is involved inmental illnesses,
we next examined PERK and ATF4 expression in the frontal
cortex of patients with bipolar disorder compared to normal
controls. In contrast to schizophrenic brains, PERK and ATF4
levels were unaltered in the frontal cortex of patients with bipolar
disorder compared to normal control patients (Figures 7C and
7D). Taken together, these findings suggest that disturbances
of PERK-regulated translation of ATF4 in the frontal cortex may
specifically contribute to the pathophysiology of schizophrenia.
Figure 7. PERK and ATF4 Expression Are Reduced in the Frontal
Cortex of Patients with Schizophrenia but Not Patients with Bipolar
Disorder
(A) PERK expression levels normalized by GAPDH levels. normal, n = 35;
schizophrenia (schizo), n = 35 (*p < 0.05, one-way ANOVA). Scatterplots
display the variability and differences in the protein expression levels
normalized by each GAPDH expression level.
(B) Gene-specific translation of ATF4 is reduced in the frontal cortex of patients
with schizophrenia. normal, n = 35; schizo, n = 33 (***p < 0.001, one-way
ANOVA).
(C) PERK expression levels do not differ between control and bipolar patient
brain samples. PERK expression normalized by tubulin levels. normal, n = 35;
bipolar, n = 35 (p > 0.05, not significant, one-way ANOVA).
(D) ATF4 expression remains unaltered in the frontal cortex of patients with
bipolar disorder compared to normal controls. normal, n = 35; bipolar, n = 35
(p > 0.05, not significant, one-way ANOVA). A crossbar on each scatterplot
represents mean expression levels for each group.
See also Tables S1 and S2.DISCUSSION
PERK is a key regulator of translation control pathways known
to be involved in learning and memory formation. Previous
studies have shown that global inactivation of PERK causes
severe developmental defects, precluding a comprehensive
analysis of its role in cellular andmolecular processes underlying
memory and cognitive function. In our studies we used the
Cre-lox expression system to achieve a temporally and spatially
restricted inactivation of Perk in the postnatal forebrain. Our find-
ings reveal a previously unrecognized role of PERK-dependent
translational regulation in cognitive function and provide molec-
ular insights into the pathophysiology of cognitive impairment.
We found that disruption of the PERK-eIF2a-ATF4 signalingpathway in the mouse PFC recapitulates multiple behavioral
phenotypes consistent with impaired cognition and information
processing. Furthermore, our studies identify the modulation of
eIF2a phosphorylation as a potential molecular target for thera-
peutic agents designed to prevent cognitive symptoms associ-
ated with a wide variety of neurological and neuropsychiatric
disorders.
Earlier studies provide strong evidence to suggest that
gene-specific translation of ATF4 is critical for the modulation
of hippocampus-dependent long-term synaptic potentiation
andmemory formation. In particular, transgenic mice expressing
a dominant-negative inhibitor of C/EBP proteins were reported
to have reduced ATF4 expression, which was associated with
a facilitation of hippocampus-dependent long-term synaptic
plasticity and memory formation (Chen et al., 2003). Moreover,
a reduction of ATF4 expression in mice lacking the eIF2a kinase
GCN2 and heterozygous knockin mice with a mutation on serine
51 of eIF2a results in a lowered threshold for eliciting long-lasting
LTP and memory (Costa-Mattioli et al., 2005, 2007). Taken
together, these studies suggest that regulation of ATF4 expres-
sion,mediated byGCN2-dependent phosphorylation of eIF2a, is
required for activity-dependent, enduring changes in neuronal
function. Expanding on these findings, we show that in the
PFC of PERK-deficient mice, reduced eIF2a phosphorylation
and ATF4 expression are associated with severe behavioral
inflexibility. Thus, our data suggest that the regulation of ATF4
mRNA translation, mediated by PERK-directed phosphorylation
of eIF2a, is critical for normal cognitive function. Because of its
conserved role as a memory repressor in diverse phyla (Bartsch
et al., 1995; Chen et al., 2003; Costa-Mattioli et al., 2005; Yin
et al., 1994), we speculate that ATF4 normally acts to destabilize
the initial memory trace, and consequently, when ATF4 expres-
sion is reduced in the PFC, the initial memory trace prevails
despite changes in sensory and contextual information.
Our data suggest that reduction of PERK expression and
ATF4 translation in the frontal cortex may specifically contribute
to the pathophysiology of human schizophrenia (Figure 7). Inter-
estingly, ATF4 has previously been shown to interact with
Disrupted-In-Schizophrenia 1 (DISC1) (Chubb et al., 2008; Muir
et al., 2008; Sawamura et al., 2008), a genetic risk factor for
mental illnesses, including mood disorders and schizophrenia.
In additionmutations in selective regions of theDISC1gene result
in a loss of interaction with ATF4 (Morris et al., 2003). Moreover,
the ATF4 gene is positioned at chromosome 22q13, a hot spot
for several schizophrenia-related susceptibility genes (Lewis
et al., 2003; Mowry et al., 2004; Williams et al., 2003). Finally,
polymorphisms in the ATF4 locus have been associated with
schizophrenia in male patients (Qu et al., 2008). Thus, multiple
studies support the notion that ATF4, whose translation is tightly
regulated by eIF2a phosphorylation, is correlated with schizo-
phrenia. It should be noted that in addition to the central regulator
ATF4, other genes recently have been identified that are prefer-
entially translated by eIF2a phosphorylation, which suggests
that additional factors participate downstream of PERK to regu-
late cognitive function (Dey et al., 2010; Jackson et al., 2010).
Behavioral studies with the PERK mutant mice revealed
multiple phenotypes consistent with cognitive and information-
processing deficits, which have been implicated as core featuresCell Reports 1, 676–688, June 28, 2012 ª2012 The Authors 683
of numerous mental illnesses, including schizophrenia, bipolar
disorder, attention deficit/hyperactivity disorder (ADHD), and
autism spectrum disorder (ASD) (Bora et al., 2009; Goos et al.,
2009; Lesh et al., 2011; Solomon et al., 2009). In particular
PERK-deficient mice exhibited reduced PPI (Figure 3A), a
sensorimotor-gating mechanism that restricts processing of
sensory information (Bitsios et al., 2006; Braff et al., 2001). In
addition PERK cKO mice showed enhanced preference
for the familiar object compared with the novel object in a
hippocampus- and entorhinal cortex-dependent novel object
recognition task (Figure 3B). One explanation for these results
is that PERK is important for frontal and temporal cortex-
dependent sensory information processing. Thus, in the absence
of PERK, mice are unable to inhibit responses to sensory or
cognitive information and have enhanced perseveration. Consis-
tent with this notion, our results from the MWM and Ymaze tests
indicate that PERK cKO mice have reduced inhibitory control
of a previously reinforced response, which causes enhanced
perseveration, impaired reversal learning, and behavioral inflexi-
bility (Figures 3C and 4A; Movies S2 and S4). Furthermore, the
results fromour fear extinction studies highlight an equally impor-
tant role for PERK in PFC-directed updating of behavior (Fig-
ure 4C). Collectively, these results suggest that PERK regulates
sensory information processing, thereby inducing deficits in
various cognitive paradigms when eliminated.
Previous studies have shown that a reduction of eIF2a phos-
phorylation inmice lacking the eIF2a kinase GCN2 and in hetero-
zygous knockin mice with a mutation on serine 51 of eIF2a
results in a lowered threshold for the consolidation of long-
term memory (Costa-Mattioli et al., 2005, 2007). Similar to the
PERK cKO mice, GCN2 and eIF2a-S51A mutant mice showed
reduced eIF2a phosphorylation and ATF4 expression, although
these reductions were global and constitutive rather than fore-
brain specific and postdevelopmental. However, the behavioral
phenotypes of the GCN2 and eIF2a-S51A mutant mice were
quite different from the PERK cKO mice. Unlike the PERK cKO
mice, we found that GCN2 KO mice showed normal reversal
learning in the Y-water maze reversal task (Figure S5). These
complementary studies indicate that even in the face of similar
biochemical profiles, such as reduced eIF2a phosphorylation
and ATF4 expression, additional mechanisms and levels of regu-
lation exist to further modulate pools of eIF2a that are eventually
reflected by distinct behavioral phenotypes. It also is important
to emphasize that the PERK cKO mice are postdevelopmental
knockout mice where the disruption of PERK occurs approxi-
mately 2–3 weeks after birth. In contrast, GCN2 KO and
eIF2a-S51A mutant mice, as well as PKR (another eIF2a kinase)
KO mice, are all global, constitutive knockout mice. Thus, the
behavioral phenotypes displayed by the GCN2, eIF2a-S51A,
and PKR mutant mouse lines could be due to developmental
complications, whereas the PERK cKO mice are not.
One current model for the pathophysiology of PCP-induced
psychosis and schizophrenia involves the hypofunction of
NMDAR in GABAergic fast-spiking interneurons (Belforte et al.,
2010; Lisman et al., 2008; Nakazawa et al., 2012). Loss of
NMDAR function in interneurons is thought to result in disinhibi-
tion of pyramidal neurons in the cortex and hippocampus, asyn-
chronous pyramidal neuron activation, hyperexcitability of684 Cell Reports 1, 676–688, June 28, 2012 ª2012 The Authorscortical networks, and cognitive impairment. Intriguingly, our
findings suggest that whereas selective ablation of PERK in
pyramidal neurons does not alter NMDAR function (Figures 5A
and 5B), chronic NMDAR hypofunction elicits a decrease of
eIF2a phosphorylation in the PFC (Figures 5C and 5D). Based
on these results, we speculate that NMDAR hypofunction in
interneurons causes cortical excitation, dysregulation of PERK,
and decreased eIF2a phosphorylation in pyramidal neurons,
resulting in impaired cognition. Consistent with this notion, a
recent study showed that deletion of the eIF2a kinase PKR in
mice results in reduced GABAergic transmission, increased
network excitability, and altered cognition (Zhu et al., 2011).
However, whether selective ablation of PERK in pyramidal
neurons associates with altered cortical network excitability
remains to be determined. Furthermore, it is possible that
reduced NMDAR function causes a disruption of PERK-directed
translation specifically in GABAergic interneurons to dampen
inhibitory control of pyramidal neurons and impair cognitive
function. Future studies examining the role of PERK in various
neuronal subtypes, in particular GABAergic interneurons, will
provide molecular insight into the role of eIF2a in the pathophys-
iology of cognitive impairment associated with multiple neuro-
logical disorders.
Interestingly, it has been shown that enhancement of NMDAR
function by treatment with the GlyT1 inhibitor SSR504734
improves behavioral flexibility, reversal learning, and overall
cognitive function (Black et al., 2009; Depoorte`re et al., 2005;
Singer et al., 2009). Consistent with these studies, our findings
indicate that SSR504734 uniquely enhanced behavioral flexi-
bility (Figures 6A and 6B; Movies S5 and S6) without altering
enhanced vertical activity and sensorimotor-gating impair-
ments displayed by the PERK cKO mice. Furthermore, chronic
SSR504734 treatment was found to restore aberrant eIF2a
phosphorylation and ATF4 expression, but not disrupted PERK
levels in the PFC of PERK cKO mice (Figures 6C–6E). Thus,
our results indicate that chronic inhibition of GlyT1 can normalize
disrupted PERK-regulated translation, presumably by either
activating other eIF2a kinases such as GCN2 and/or PKR, or
by inhibiting the protein phosphatase 1/GADD34 complex that
dephosphorylates eIF2a (Ma and Hendershot, 2003). Future
studies are required to address whether chronic SSR504734
treatment enhances GCN2 activity, enhances PKR activity, or
inhibits protein phosphatase 1/GADD34 complex in the PFC of
PERK mutant mice.
Under normal physiological conditions it has been reported
that systemic administration of SSR504734 improves behavioral
flexibility and cognitive function in WT mice (Singer et al., 2009).
In contrast we found that although chronic SSR504734 treat-
ment had no effect on the performance of the WT mice, it
restored the behavioral flexibility of the PERK cKO mice (Fig-
ure 6A). Moreover, we found that SSR504734 could not only
rescue the behavioral deficits but also could restore the
molecular anomalies exhibited by the PERK cKO mice (Figures
6D and 6E). Thus, our findings provide direct evidence that
SSR504734 can modulate eIF2a phosphorylation and ATF4
expression that are tightly correlated with reversal of the behav-
ioral inflexibility displayed by the PERK cKO mice. Future
studies are required to determine whether chronic SSR504734
treatment can restore the dysregulated eIF2a-ATF4 axis in WT
mice treated chronically with agents such as MK-801 and PCP
that induce NMDAR hypofunction and are used to model
schizophrenia.
A rapidly expanding list of neurological disorders and
neurodegenerative diseases including Alzheimer’s disease,
Parkinson’s disease, fragile X syndrome, TSC, and ASD has
been linked to dysregulated protein synthesis (Auluck et al.,
2010; Hoeffer and Klann, 2010; Kelleher and Bear, 2008; Ozcan
et al., 2008; Palop and Mucke, 2010; Santini and Klann, 2011).
Consistent with these findings, our results suggest that postde-
velopmental disruption of PERK-regulated translational control
is sufficient to trigger cognitive control impairments consistent
with several disorders, including schizophrenia. In conclusion
these findings emphasize the critical importance of PERK in
normal cognitive processes. Further studies elucidating the
specific role of PERK-regulated translation in the brain may
provide new avenues to tackle such widespread and often debil-
itating neurological disorders.
EXPERIMENTAL PROCEDURES
Transgenic Mice
Floxed Perk (PerkloxP/loxP) mice were generated as described previously
by Zhang et al. (2002). Mice expressing the Cre recombinase transgene
(T-29-1), referred to asCamkIIa-Cre, were kindly provided by Dr. S. Tonegawa
(Tsien et al., 1996). PERK cKO and WT littermate control mice were on a C57/
Bl6 genetic background that was backcrossed for more than ten generations.
For all molecular and behavioral experiments, adult mice 2–5 months of age
were used, unless otherwise noted. Mice were maintained in accordance
with the Guide for the Care and Use for Laboratory Animals from the NIH.
Genotyping
Genotyping of mice was performed using standard procedures. Please see
Extended Experimental Procedures for details.
Western Blotting
Western blots were performed using standard procedures as described previ-
ously by Banko et al. (2005). Please see Extended Experimental Procedures
for details.
IHC and Nissl Staining
IHC and Nissl staining were performed using standard procedures. Please see
Extended Experimental Procedures for details.
SUnSET Technique
Proteins were labeled using an adaptation of the SUnSET method by Schmidt
et al. (2009). Briefly, 400 mm coronal prefrontal slices from WT and PERK cKO
mice were prepared using a vibratome, slices were allowed to recover in arti-
ficial cerebral spinal fluid (ACSF) at 32C for 1 hr, and subsequently treated
with puromycin (P8833 [Sigma-Aldrich, St. Louis] 5 mg/ml) for 45 min. Reac-
tions were stopped by flash freezing the slices on dry ice. Proteins were
prepared, blotted, and quantified as described above (see Western Blotting),
and 50 mg of puromycin-labeled protein was resolved on 4%–12% gradient
gels (Invitrogen) and visualized using an antibody specific to puromycin
(12D10; see Western Blotting). Protein synthesis levels were determined by
taking the total lane signal from 15 to 250 kDa and subtracting the signal
from the control lane that was not labeled by puromycin. Comparisons of
protein synthesis levels between both genotypes were made by normalizing
to the average WT signal obtained from different experimental replicates.
Polysome Analysis
Three pairs of 3-week-old PERK cKOmice and theirWT littermates were termi-
nally anesthetized by isoflurane, and polysome gradients were prepared.Briefly, postmitochondrial supernatants of PFC, dissected free from white
matter, were prepared and separated by sucrose density gradients
(20%–50%). Gradients were centrifuged at 4C for 2 hr at 40,000 rpm in an
SW41 rotor. Then, 890 ml fractions (16 per gradient) were collected with
continuous monitoring of UV absorbance at 254 nm (UA-6 absorbance
detector; ISCO).
PPI
Sensorimotor gating wasmeasured by testing the startle response and the PPI
of the startle response. Mice were placed individually in a Plexiglas cylinder
connected to a startle detector. Upon habituating to the background noise
(70 dB), each mouse was presented with a semirandom series of prepulses
of varying intensities (74, 78, 82, 86, and 90 dB) paired with an acoustic startle
stimulus (120 dB). The percent (%) PPI was calculated as follows: (1  (startle
response to prepulse+pulse)/(startle response to pulse alone)) 3 100.
Novel Object Recognition
Novel object recognition experiments were performed as previously described
by Hoeffer et al. (2008). The novel object recognition task is based on the
natural tendency of mice to explore a novel object rather than a familiar object.
The amount of time spent exploring the novel object was divided by the total
time spent exploring both objects to generate a preference index that was
multiplied by 100 to calculate percent object preference. The Noldus
EthoVision software and video-tracking system were used to monitor and
record object interaction time.
MWM Reversal Learning Task
MWM experiments were performed as previously described by Banko et al.
(2005), and the reversal learning protocol was adapted from previous studies
by Hoeffer et al. (2008). Escape latency, number of previous platform position
crossing, time spent in each quadrant, and trajectories of the mice were
recorded with a computerized video-tracking system (Noldus EthoVision).
Briefly, the paradigm consisted of a 9 day training period broken into several
phases. On days 1–5 (reference), mice were trained to locate a submerged
hidden platform. Following completion of the last training trial on day 5,
a single-probe trial was given by removing the hidden platform from the
pool. On days 6 and 7 (reversal), the originally learned platform location was
moved to the opposite quadrant. On days 8 and 9 (visible), mice were tested
using a visible cue. During reference, reversal, and visible phases, mice
were given four trials per day (60 s maximum, intertrial interval [ITI] 15 min).
Y-Water Maze Arm Reversal Task
Arm reversal in the Y-water maze task was carried out as described previously
by Hoeffer et al. (2008). A retraining paradigmwas incorporated to allow the 12
out of 13 PERK cKO mice that perseverated to make 3 consecutive correct
choices (Figure 4A). This entailed using a Plexiglas wall to section off the incor-
rect arm choice. Once three consecutive correct choices were made, the wall
was removed, and mice were tested to determine the latency to find the new
escape location. For the immediate arm reversal task (Figure 4B), 4-month-old
PERK cKO mice and their WT littermates were trained to locate an escape
platform placed in one arm of the Y maze with a slight modification. Following
acquisition the escape platform was switched on the same day (immediate),
and the behavioral flexibility of the mice to learn the new escape location
was measured.
Fear Extinction
Prior to extinction training, mice were fear conditioned by training them
to associate two CS-US pairings separated by 1 min (foot-shock intensity
[US]: 0.65 mA, 2 s duration; tone [CS]: 85 dB white noise, 30 s duration). The
following day, mice were placed in an environmentally altered training
chamber and received 2 extinction training sessions consisting of 15 consec-
utive CS presentations with an average ITI between CSs of 120 s and a 24 hr
interval between each session. Twenty-four hours after the last extinction
training session (day 3), mice were returned to testing chamber and presented
with an LTM test (two tone alone trials). Freezing was recorded continuously
during the 15 extinction training trials and 2 trial LTM test sessions. Freezing
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Intracellular Electrophysiology
Whole-cell recordings frommPFCpyramidal cells from layer II were conducted
using standard procedures. Please see Extended Experimental Procedures for
details.
Human Samples
Protein samples extracted from the dorsolateral PFC (DLPFC; Brodmann Area
46) of 35 individuals in each of the three diagnostic groups (schizophrenia,
bipolar disorder, and unaffected controls) were obtained from the SMRI Array
Collection. These specimens were collected, with informed consent from next
of kin, by participating medical examiners between January 1995 and June
2002. All groups were matched for age, sex, and race. A summary of the
relevant patient demographic information is provided in Table S1. The speci-
mens were collected, processed, and stored in a standardized way. Proteins
were extracted using a protease inhibitor-Tris-glycerol extraction buffer
(AEBSF 0.048%, aprotinin 0.01%, leupeptin 0.002%, pepstatin A 0.001%,
glycerol 50%, Tris Ultra Pure 1.2%) (0.1 g brain tissue: 1.25 ml buffer). Analysis
of 20 mg protein samples from schizophrenia (n = 35), bipolar (n = 35), and unaf-
fected controls (n = 35) was conducted; the samples were coded such that the
investigator was blind to diagnostic status. Upon decoding, no signal was
detected in two samples from the schizophrenia cohort for the ATF4 analysis
and eliminated from further analysis.
Pharmacological Reagents
For protein synthesis studies using the SUnSET technique (Figure 2A), coronal
prefrontal slices fromWT and PERK cKOmice were incubated with puromycin
(P8833, 5 mg/ml) for 45 min. For NMDA hypofunction studies (Figures 5C and
5D), C57/Bl6WTmicewere given either a single (acute) or 15 daily (chronic) i.p.
injections of vehicle (0.9% saline) or MK-801 dissolved in vehicle (Sigma-
Aldrich; 0.2 mg/kg for acute studies and 0.1 mg/kg for chronic studies).
SSR504734, a GlyT1 inhibitor compound, was provided by Sanofi-Aventis
(Paris) and dissolved in water with a few drops of Tween 80 as previously
described by Depoorte`re et al. (2005). For behavioral and molecular rescue
studies (Figure 6), injections of SSR504734 (20 mg/kg) were given i.p. to
PERK cKO and WT littermates for 21 days prior to behavioral testing and
protein expression analysis.
Statistical Analysis
All data are presented as the mean ± SEM. Statistical analyses between
two groups were performed by using a two-tailed Student’s t test. Com-
parisons involving drug treatment, time courses, or protein expression among
multiple groups or genotypes were performed with a one- or two-way ANOVA.
For the human studies, potential association of continuous variables such as
age, brain pH, PMI, and lifetime antipsychotic usage was determined using
Spearman correlation coefficients. Significance criteria of p < 0.05 were
used for all data analysis. Extreme outliers were detected by applying Grubbs’
method with a = 0.05 to each experimental group and eliminated from further
analysis (GraphPad software).
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